Form 4: Caris Life Sciences Director Boosts Stake

Caris Life Sciences Director Peter M. Castleman acquired 5,509 shares of common stock as compensation for board retainer fees.

Summary

• Director Peter M. Castleman acquired 5,509 shares of Caris Life Sciences, Inc. common stock.
• The shares were issued on February 26, 2026, at a price of $20.06 per share.
• This acquisition represents compensation for 2025 board retainer fees, calculated based on the ten trading day average of the daily volume-weighted average price per share through and including February 25, 2026.
• Following this transaction, Mr. Castleman directly owns 24,138 shares.
• He also indirectly beneficially owns 100,000 shares through a Family Trust and 10,270,906 shares through CLS-PF-SPE, LLC, where he is a manager of the managing entity, though he disclaims beneficial ownership except to the extent of his pecuniary interest therein.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a slightly positive event, as a director increasing their stake, even through compensation, generally signals alignment with shareholder interests and confidence in the company.

Positives

• Director Peter M. Castleman increased his direct beneficial ownership by 5,509 shares, aligning his interests further with shareholders.
• The acquisition was part of a compensation plan, indicating a structured approach to director remuneration.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that insider transactions, such as a director increasing their stake, are often viewed by the market as a signal of confidence in the company's future prospects, although this specific transaction is for compensation rather than an open market purchase.

Related Party Transactions

• Director Peter M. Castleman received 5,509 shares of common stock as compensation for his 2025 board retainer fees, which constitutes a transaction between the company and a related party (a director).

Stakeholder Impact

• Shareholders: Slight dilution from the issuance of new shares for compensation, but also potential positive signal from increased insider ownership.
• Employees: No direct impact mentioned.
• Customers: No direct impact mentioned.
• Suppliers: No direct impact mentioned.
• Creditors: No direct impact mentioned.

Key Dates

Keywords

Caris Life Sciences, CAI, Peter M. Castleman, Director, Insider Trading, Form 4, Stock Acquisition, Compensation, Beneficial Ownership